研究成果： |
近年来主持国家自然科学基金面上项目、国家科技重大专项子课题、吉林省科技发展计划项目等10余项；发表SCI论文40余篇，其中以通讯作者在STTT、Cancer Letters、Acta Biomaterialia等高水平期刊发表研究论文20余篇；以第一发明人申请国家发明专利6项（已授权3项）；获得吉林省科学技术奖一等奖1项（排名9）、二等奖1项（排名2）；当选中华医学会医学病毒学分会第十届青委会委员（2021）；兼任Frontiers in Microbiology客座编辑（2020-2021），及ACS Nano、Cancer Letters等杂志审稿人。 主持项目情况： 1. 国家自然科学基金面上项目，神经干细胞源生物膜修饰溶瘤腺病毒靶向治疗恶性胶质瘤的研究，2021-01-01至2024-12-31，58万元，在研，主持 2. 吉林省科技发展计划国际科技合作项目，HIV-1广谱中和抗体的分离与性质研究，2021-07-01至2024-06-30，15万元，在研，主持 3. “十三五”国家科技重大专项校内子课题，可诱导广谱中和抗体的gp120蛋白三聚体研究-2，2019-01-01至2020-12-31，55万元，结题，主持 4. “十三五”国家科技重大专项校内子课题，DNA和BLP-gp120蛋白疫苗的生产和评价-3，2018-01-01至2020-12-31，80万元，结题，主持 5. 国家自然科学基金面上项目，新型双级脑靶向溶瘤腺病毒载体设计及其治疗恶性胶质瘤的研究，2017-01-01至2020-12-31，58万元，结题，主持 6. 吉林省科技发展计划自然科学基金，重组8型腺相关病毒载体介导CDNF和AADC联合治疗帕金森病大鼠模型实验研究，2016-01-01至2018-12-31，10万元，结题，主持 7. “十二五”国家科技重大专项校内子课题，以survivin和MUC1为靶点肿瘤治疗性基因疫苗的有效性研究，2015-01-01至2016-12-31，30万元，结题，主持 8. 国家自然科学基金青年科学基金，腺病毒衣壳蛋白特异性中和抗体性质及血清型特异中和抗原确认的研究，2014-01-01至2016-12-31，23万元，已结题，主持 9. “十二五”国家科技重大专项校内子课题，多肽-重组流感疫苗Ⅰ期临床样本检测，2013-06-01至2015-05-31，50万元，已结题，主持 10. 中国博士后科学基金第七批特别资助，2014年度，15万元，生物工程，结题，主持 近五年论文： 1. Wenmo Liu, Xupu Wang, Xinyao Feng, Jiahao Yu, Xinyao Liu, Xinyuan Jia, Haihong Zhang, Hui Wu, Chu Wang, Jiaxin Wu,Bin Yu∗and Xianghui Yu∗. Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models. Cancer Letters. 535 (2022) 215661. (中科院1区，IF= 8.679) 2. Xinyao Feng, Fangshen Li, Liangliang Zhang, Wenmo Liu, Xupu Wang, Rui Zhu, Zhen-An Qiao,Bin Yu∗, Xianghui Yu∗. TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy. Acta Biomaterialia. 143 (2022) 392–405. (中科院1区，IF= 8.947) 3. Huaiyu Wang, Pingchao Li, Mo Zhang, Jinpeng Bi, Yizi He, Fangshen Li, Rongzhen Yu, Feng Gao, Wei Kong,Bin Yu∗, Ling Chen∗, Xianghui Yu∗. Vaccine with bacterium-like particles displaying HIV-1 gp120 trimer elicits specific mucosal responses and neutralizing antibodies in rhesus macaques. Microbial Biotechnology. 2022, Mar 15. doi: 10.1111/1751-7915.14022. (中科院2区，IF= 5.813) 4. Zixuan Wang, Wenmo Liu, Lizheng Wang, Peng Gao, Zhe Li, Jiaxin Wu, Haihong Zhang, Hui Wu, Wei Kong, Bin Yu∗, Xianghui Yu∗. Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia. Signal Transduction and Targeted Therapy. 2020, 5(1):40. (中科院1区，IF= 18.1873) 5. Jinpeng Bi, Fangshen Li, Mo Zhang, Huaiyu Wang, Jingcai Lu, Yong Zhang, Hong Ling, Jiaye Wang, Feng Gao, Wei Kong,Bin Yu∗, Xianghui Yu∗. An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses. Immunology Letters. 2020, 222:29-39. 6. Lizheng Wang, Wenmo Liu, Zhe Li, Xupu Wang, Xinyao Feng, Zixuan Wang, Jiaxin Wu, Haihong Zhang, Hui Wu, Wei Kong,Bin Yu∗, Xianghui Yu∗. A tropism-transformed Oncolytic Adenovirus with Dual Capsid Modifications for enhanced Glioblastoma Therapy. Journal of Cancer. 2020, 11(19):5713-5726. 7. Lizheng Wang, Zixuan Wang, Rui Zhu, Jinpeng Bi, Xinyao Feng, Wenmo Liu, Jiaxin Wu, Haihong Zhang, Hui Wu, Wei Kong,Bin Yu∗, Xianghui Yu∗. Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression. PLoS One. 2017, 12(6):e0179476. 8. Lizheng Wang, Zixuan Wang, Xiaoyu Xu, Rui Zhu, Jinpeng Bi, Wenmo Liu, Xinyao Feng, Hui Wu, Haihong Zhang, Jiaxin Wu, Wei Kong,Bin Yu∗, Xianghui Yu∗. Recombinant AAV8-mediated intrastriatal gene delivery of CDNF protects rats against methamphetamine neurotoxicity. Int J Med Sci. 2017, 14(4):340-347. 9. Jingyi Yan, Lizheng Wang, Zixuan Wang, Zhen Wang, Baoming Wang, Rui Zhu, Jinpeng Bi, Jiaxin Wu, Haihong Zhang, Hui Wu,Bin Yu∗, Wei Kong, Xianghui Yu∗. Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity, Cell Death and Disease, 2016, 7(6): e2274. 10. Zhen Wang#,Bin Yu#, Baoming Wang, Jingyi Yan, Xiao Feng, Zixuan Wang, Lizheng Wang, Haihong Zhang, Hui Wu, Jiaxin Wu, Wei Kong, Xianghui Yu. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route. Oncotarget, 2016, 7(30):47287-47301. 11. Jingyi Yan, Jianing Dong, Jiaxin Wu, Rui Zhu, Zhen Wang, Baoming Wang, Lizheng Wang, Zixuan Wang, Haihong Zhang, Hui Wu,Bin Yu∗, Wei Kong, Xianghui Yu∗. Interaction between hexonand L4-100K determines virus rescue and growth of hexon-chimeric recombinant Ad5 vectors, Scientific Reports, 2016, 6: 22464-22477. 12. Shuai Lang, Lizheng Wang, Zixuan Wang, Rui Zhu, Jingyi Yan, Baoming Wang, Jiaxin Wu, Haihong Zhang, Hui Wu, Yan Zhou, Wei Kong,Bin Yu* and Xianghui Yu*. Localization of neutralization epitopes on adenovirus fiber knob from species C. Journal of General Virology. 2016, 97: 955-962. 13. Lizheng Wang, Zixuan Wang, Fangfang Zhang, Rui Zhu, Jinpeng Bi, Jiaxin Wu, Haihong Zhang, Hui Wu, Wei Kong,Bin Yu*, Xianghui Yu*. Enhancing Transgene Expression from Recombinant AAV8 Vectors in Different Tissues Using Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element. Int J Med Sci. 2016, 13(4): 286-291. 科技奖励： 1. 于彬（2/7）；恶性肿瘤的发病机制和生物治疗研究，吉林省科学技术奖二等奖（2021） 2. 于彬（9/10）；HIV感染机制和人体对HIV免疫保护机制的研究，吉林省科学技术奖一等奖（2013） 3. 于彬（6/10）；艾滋病病毒辅助蛋白与宿主限制因子相互作用研究，吉林省自然科学学术成果奖一等奖（2014） 4. 于彬（5/9）；腺病毒载体的预存免疫及解决策略的相关研究，吉林省自然科学学术成果奖二等奖（2013） |
